295 related articles for article (PubMed ID: 35880977)
1. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
Ramtohul T; Tescher C; Vaflard P; Cyrta J; Girard N; Malhaire C; Tardivon A
Radiology; 2022 Dec; 305(3):565-574. PubMed ID: 35880977
[TBL] [Abstract][Full Text] [Related]
2. Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.
Ren Z; Pineda FD; Howard FM; Fan X; Nanda R; Abe H; Kulkarni K; Karczmar GS
Magn Reson Imaging; 2023 Dec; 104():9-15. PubMed ID: 37611646
[TBL] [Abstract][Full Text] [Related]
3. Early prediction of pathologic complete response of breast cancer after neoadjuvant chemotherapy using longitudinal ultrafast dynamic contrast-enhanced MRI.
Cao Y; Wang X; Li L; Shi J; Zeng X; Huang Y; Chen H; Jiang F; Yin T; Nickel D; Zhang J
Diagn Interv Imaging; 2023 Dec; 104(12):605-614. PubMed ID: 37543490
[TBL] [Abstract][Full Text] [Related]
4. Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer.
Kim JH; Park VY; Shin HJ; Kim MJ; Yoon JH
Eur Radiol; 2022 Jul; 32(7):4823-4833. PubMed ID: 35064805
[TBL] [Abstract][Full Text] [Related]
5. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
6. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
Partridge SC; Zhang Z; Newitt DC; Gibbs JE; Chenevert TL; Rosen MA; Bolan PJ; Marques HS; Romanoff J; Cimino L; Joe BN; Umphrey HR; Ojeda-Fournier H; Dogan B; Oh K; Abe H; Drukteinis JS; Esserman LJ; Hylton NM;
Radiology; 2018 Dec; 289(3):618-627. PubMed ID: 30179110
[TBL] [Abstract][Full Text] [Related]
7. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
Li Y; Chen Y; Zhao R; Ji Y; Li J; Zhang Y; Lu H
Eur Radiol; 2022 Mar; 32(3):1676-1687. PubMed ID: 34767068
[TBL] [Abstract][Full Text] [Related]
10. MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
Wang M; Du S; Gao S; Zhao R; Liu S; Jiang W; Peng C; Chai R; Zhang L
Breast Cancer Res; 2024 Feb; 26(1):26. PubMed ID: 38347619
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy.
Kim SY; Cho N; Park IA; Kwon BR; Shin SU; Kim SY; Lee SH; Chang JM; Moon WK
Radiology; 2018 Nov; 289(2):327-334. PubMed ID: 30152744
[TBL] [Abstract][Full Text] [Related]
12. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
[TBL] [Abstract][Full Text] [Related]
13. Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram.
Kim SY; Cho N; Choi Y; Lee SH; Ha SM; Kim ES; Chang JM; Moon WK
Radiology; 2021 May; 299(2):290-300. PubMed ID: 33754824
[TBL] [Abstract][Full Text] [Related]
14. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
[TBL] [Abstract][Full Text] [Related]
15. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
[TBL] [Abstract][Full Text] [Related]
16. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Li W; Newitt DC; Wilmes LJ; Jones EF; Arasu V; Gibbs J; La Yun B; Li E; Partridge SC; Kornak J; ; Esserman LJ; Hylton NM
J Magn Reson Imaging; 2019 Dec; 50(6):1742-1753. PubMed ID: 31026118
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Pathologic Response Evaluation Systems After Neoadjuvant Chemotherapy in Breast Cancers: Correlation With Computer-Aided Diagnosis of MRI Features.
Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
AJR Am J Roentgenol; 2019 Oct; 213(4):944-952. PubMed ID: 31237439
[No Abstract] [Full Text] [Related]
18. Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging.
Han X; Yang H; Jin S; Sun Y; Zhang H; Shan M; Cheng W
Cancer Med; 2023 Jan; 12(2):1389-1398. PubMed ID: 35822639
[TBL] [Abstract][Full Text] [Related]
19. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
Cain EH; Saha A; Harowicz MR; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2019 Jan; 173(2):455-463. PubMed ID: 30328048
[TBL] [Abstract][Full Text] [Related]
20. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
Kazerouni AS; Peterson LM; Jenkins I; Novakova-Jiresova A; Linden HM; Gralow JR; Hockenbery DM; Mankoff DA; Porter PL; Partridge SC; Specht JM
Breast Cancer Res; 2023 Nov; 25(1):138. PubMed ID: 37946201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
